Given the importance of their interaction for the tumorigenicity of ovarian cancer cells, MUC16 and mesothelin have emerged as putative targets for developing treatments for peritoneal metastasis in epithelial ovarian cancer [14, 15]. This evidence concerns the gene MSLN and ovarian cancer.